Top Story

FDA approves Viekira Pak for treatment of HCV

December 19, 2014

The FDA today approved a treatment for patients with hepatitis C virus genotype 1 infection, including those with cirrhosis, according to a press release.

A combination of ombitasvir, paritaprevir and ritonavir tablets with dasabuvir tablets (Viekira Pak, AbbVie) is the fourth chronic HCV drug product the FDA has approved in the past 14 months, and the 11th drug to have previously received the FDA’s breakthrough therapy designation. It can be used with or without ribavirin, but is not recommended for patients with decompensated cirrhosis.

Veena L. Venkat, MD

Eight developments in pediatric GI conditions

December 19, 2014
Recent study data on pediatric gastrointestinal conditions have been abundant, particularly among presentations at the many gastroenterological society meetings this…

CMS releases new quality of care data on physicians, ACOs, hospitals

December 19, 2014
CMS released new data on the quality of care provided by physician group practices, hospitals and Accountable Care Organizations, according to the CMS Blog.Included in…

CDC, FDA: Multistate listeriosis outbreak linked to caramel apples

December 19, 2014
The CDC and FDA announced an ongoing investigation of an outbreak of listeria infections associated with commercially produced, prepackaged caramel apples.As of Dec. 18…

Majority of US high school students get insufficient sleep

December 19, 2014
Less than 10% of US high school students reportedly obtain at least 9 hours of sleep nightly, according to data in Preventing Chronic Disease, suggesting the majority…
More News Headlines »
Short Subjects

Eyelid Basal Cell Carcinoma in a Healthy Child

Journal of Pediatric Ophthalmology and Strabismus, Volume -2147483648
Online Only, December 12, 2014
Basal cell carcinoma is rare in children and usually is associated with genetic or immune predisposing factors. A…
More »
CME
Cover

Updates in Systemic Juvenile Idiopathic Arthritis: What New Guidelines Mean to Your Practice

This activity is supported by an educational grant from Genentech, Inc.

Systemic juvenile idiopathic arthritis (JIA) accounts for 5% to 15% of patients diagnosed with JIA and is the most…
More »
Meeting News Coverage Video
RIVUR: Antimicrobial prophylaxis associated with reduced risk for recurrence, comparable renal scarring

RIVUR: Antimicrobial prophylaxis associated with reduced risk for recurrence, comparable renal scarring

December 4, 2014
NEW YORK — Sarah Long, MD, section chief of Infectious Diseases at St. Christopher’s Hospital for Children…
More »
morganatic-roan